Chase AIPricingFAQs
Display currency
Loading news…

Ad Scientiam

ActiveOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down.🔥 HighHeat score — how much recent activity & attention the company has (web traffic, news, hiring).📈 Low growthGrowth score — momentum trend across web traffic, headcount and other growth signals.
Paris, Ile-de-France, France Founded 2013 51-100 employees For Profit

Ad Scientiam develop reliable solutions to measure disease evolution to accelerate treatment decisions to fight the disabilities.

Total Funding
Available in Pro
Last Funding
Available in Pro
Acquisitions
0
Monthly Visits
Available in Pro
Contacts
32

Company Details

Funding & Financials

Pro
Total funding
Funding rounds
Last funding
Last funding type
Last funding date
Funding status
Total equity funding
Revenue range

IPO & Stock

IPO status
Private

Web Traffic

Pro
Monthly visits
Global traffic rank
6-mo avg visits
Visit duration (s)
Pages / visit
Bounce rate
Rank change (mo)

Technology & IP

Active technologies
85
Mobile apps
14
Downloads (30d)
11
Active products
15
IT spend
$421K

Company Info

Founded
2013
Employees
51-100
Operating status
Active
Company type
For Profit
Org types
company
Founders
2
News articles
11
Events
2
HQ
Paris, Ile-de-France, France
Region
European Union (EU), Europe, Middle East, and Africa (EMEA)

Signals & Scores

Heat score
High
Growth score
Low
Trend (7d)
-0.3
Trend (30d)
2.7
Trend (90d)
2.3

Key People at Ad Scientiam

Chief Medical Officer
Chief eXperience Officer & Co-founder
32
professional contacts at Ad Scientiam
Contact execs at Ad Scientiam

Explore 200,000+ acquisitions — free

Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.

Explore all acquisitions

Recent News related to Ad Scientiam

Loading news…

FAQs about Ad Scientiam

People who checked this page also checked these

Browse the full Acquirezy directory.
Ad Scientiam - Company Profile, Full Acquisitions List, Funding and Investments